Tauriga Sciences, Inc. Completes Payment for the Entirety of its Initial Production Run of its Pear Bellini Flavor Tauri-Gum
11 July 2020 - 1:34AM
InvestorsHub NewsWire
Tauriga Sciences, Inc. Completes Payment for the Entirety
of its Initial Production Run of its Pear Bellini Flavor Immune
Booster Tauri-Gum Version
NEW YORK, NY -- July 10, 2020 -- InvestorsHub NewsWire
-- Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating,
diversified life sciences company, with a proprietary line of
functional “supplement” chewing gums (Flavors: Pomegranate, Blood
Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as
two ongoing Biotechnology initiatives, today announced that it has
completed payment for the entirety of its initial production run of
its Pear Bellini flavor – Immune Booster – version of Tauri-Gum™.
This product version is infused with 60mg Vitamin C and 10mg
Elemental Zinc (No Phyto-Cannabinoids), per each piece of chewing
gum. MSRP - $12.99 per Blister Pack.
In other news, the Company expects the official launch date of
its Rainbow Deluxe Sampler Pack – July 22,
2020. Available exclusively on the Company’s E-Commerce
website (www.taurigum.com) at a
price of $99.99.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating, diversified life sciences company, engaged
in several major business activities and initiatives. The
company manufactures and distributes several proprietary retail
products and product lines, mainly focused on the Cannabidiol
(“CBD”) and Cannabigerol (“CBG”) Edibles market
segment. The main product line, branded as Tauri-Gum™,
consists of a proprietary supplement chewing gum that is both
Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™
Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused
Tauri-Gum™ Flavor: Peach-Lemon). The Company’s
commercialization strategy consists of a broad array of retail
customers, distributors, and a fast-growing E-Commerce business
segment (E-Commerce website: www.taurigum.com). Please visit
our corporate website, for additional information, as well as
inquiries, at www.tauriga.com
Complementary to the Company’s retail business, are its two
ongoing biotechnology initiatives. The first one relates to
the development of a Pharmaceutical grade version of Tauri-Gum™,
for nausea regulation (specifically designed to help patients that
are subjected to ongoing chemotherapy treatment). On March
18, 2020, the Company announced that it filed a provisional U.S.
patent application covering its pharmaceutical grade version of
Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled
“MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS
OF TREATMENT”. The second one relates to a collaboration
agreement with Aegea Biotechnologies Inc. for the co-development of
a rapid, multiplexed, Novel Coronavirus (COVID-19) test with
superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a
regional office in Barcelona, Spain. In addition, the Company
operates a full time E-Commerce fulfillment center located in
LaGrangeville, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Instagram: @taurigum
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024